MINOXIDIL EXTRA STRENGTH (FOR MEN)

Clinical safety rating: safe

Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.

How it works

Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.

What the body does with it

Metabolism	Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Excretion	Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Half-life	Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Protein binding	About 20% bound to plasma proteins (primarily albumin).
Volume of Distribution	Approximately 3-4 L/kg, indicating extensive distribution into tissues.
Bioavailability	Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Onset of Action	Topical application: Onset of hair regrowth is usually within 3-4 months of twice-daily application. Oral administration: Onset of antihypertensive effect occurs within 30 minutes, with peak effect at 2-3 hours.
Duration of Action	Topical: Duration of effect on hair growth requires continuous application; discontinuation leads to reversal of effect within 3-4 months. Oral: Antihypertensive effect persists for approximately 24 hours with once-daily dosing.

Classification & Brands

Dosing & administration

Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: use with caution, reduce dose by 75%.
Liver impairment	No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Pediatric use	Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
Geriatric use	No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.

FDA category	Animal
Breastfeeding	Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Teratogenic Risk	Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	androgenetic alopecia
Serious Effects

Absolute Contraindications

["Hypersensitivity to minoxidil or any component of the formulation","Concurrent use with other topical hair growth products"]

Clinical Precautions

Precautions

["Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis","Hypotension: can occur if applied to broken skin or excessive application","Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis)","Cardiac: avoid in patients with known coronary artery disease or arrhythmias"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MINOXIDIL EXTRA STRENGTH (FOR MEN)

Clinical safety rating: safe

Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.

How it works

Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.

What the body does with it

Metabolism	Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Excretion	Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Half-life	Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Protein binding	About 20% bound to plasma proteins (primarily albumin).
Volume of Distribution	Approximately 3-4 L/kg, indicating extensive distribution into tissues.
Bioavailability	Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Onset of Action	Topical application: Onset of hair regrowth is usually within 3-4 months of twice-daily application. Oral administration: Onset of antihypertensive effect occurs within 30 minutes, with peak effect at 2-3 hours.
Duration of Action	Topical: Duration of effect on hair growth requires continuous application; discontinuation leads to reversal of effect within 3-4 months. Oral: Antihypertensive effect persists for approximately 24 hours with once-daily dosing.

Classification & Brands

Dosing & administration

Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: use with caution, reduce dose by 75%.
Liver impairment	No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Pediatric use	Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
Geriatric use	No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.

FDA category	Animal
Breastfeeding	Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Teratogenic Risk	Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	androgenetic alopecia
Serious Effects

Absolute Contraindications

["Hypersensitivity to minoxidil or any component of the formulation","Concurrent use with other topical hair growth products"]